BAI

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

BenevolentAI Appoints New Chief Technology Officer

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Health Technology, Professional Services, Machine learning, EBI, Elsevier, Bioinformatics, Drug discovery, University of Edinburgh, Artificial intelligence, Benevolence, AI, Doctor of Philosophy, Engineering, BAI, Family, Euronext Amsterdam, European

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.
  • The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer.
  • As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.
  • Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
    Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI.

BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice

Retrieved on: 
Wednesday, March 20, 2024
Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Account, BAI, Euronext Amsterdam, Remuneration, Documentation, AGM, Annual report, Policy

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”).

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”).
  • The 2023 Annual Report, the 2024 AGM Notice, the amended Remuneration Policy of the Company, the proxy form and any other meeting documentation are available on the Company’s website ( www.benevolent.com/investors/general-meetings/ ) and at the Company’s registered office.
  • The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of 18 April 2024 at 24:00 (midnight) CEST.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

BenevolentAI: Notice of Preliminary Results

Retrieved on: 
Monday, March 4, 2024
Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, FTI Consulting, BAI, Euronext Amsterdam, Webcast, FTI

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year ended 31 December 2023 on Thursday, 14 March 2024.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year ended 31 December 2023 on Thursday, 14 March 2024.
  • Management will host an in-person analyst briefing at 13:00 GMT (08:00 ET) on the day of the results at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom).
  • To register your interest in attending either in person or virtually, analysts should contact FTI Consulting at [email protected].
  • A recording of the webcast will be made available in the investor section of the Company’s website shortly afterwards.

Berry Aviation Secures Key Role in $946 Million Contract to Strengthen Sustainment Solutions for the U.S. Army

Retrieved on: 
Thursday, February 15, 2024
SAN, Discovery Air, DOD, AGC, Air medical services, Aviation, Investment, ISR, EASA, Part, Intelligence, CAMTS, MRO, Lead, BAI, Acorn, Commission, AGC Aerospace & Defense, MEDEVAC, Accreditation, Airline

SAN MARCOS, Texas, Feb. 15, 2024 /PRNewswire/ -- Berry Aviation, Inc (BAI) has been awarded a subcontract and key role on a $946 million dollar contract supporting the U.S. Army.

Key Points: 
  • SAN MARCOS, Texas, Feb. 15, 2024 /PRNewswire/ -- Berry Aviation, Inc (BAI) has been awarded a subcontract and key role on a $946 million dollar contract supporting the U.S. Army.
  • The contract, awarded to Amentum Services Inc. (Amentum) as the prime, includes the modernization, integration, and sustainment of a fleet of 150 fixed wing aircraft.
  • BAI, a member of Acorn Growth Companies, is headquartered in San Marcos, TX.
  • Acorn Growth Companies (AGC) is a middle market private equity firm focused exclusively on Aerospace, Defense, Space, and Intelligence.

BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer

Retrieved on: 
Wednesday, January 24, 2024
Health, Technology, Other Science, Research, Artificial Intelligence, Science, Pharmaceutical, Development, Patient, BAI, Euronext Amsterdam, Executive Committee, MD, Culture, Artificial intelligence, Benevolence, AI, Ruhr University Bochum, Drug discovery, Doctor of Philosophy, LEO, Leo Pharma, EVP, Platform, Growth, Medical device

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.

Key Points: 
  • BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.
  • Dr. Joerg Moeller, MD, PhD, brings a wealth of experience to BenevolentAI.
  • Dr. François Nader, Chair of BenevolentAI, commented: “Along with the rest of the Board, I am delighted to welcome Joerg.
  • With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”
    Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “I am excited by the opportunity to lead BenevolentAI.

BenevolentAI to present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Health, Technology, Health Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, Q&A, Conference, Euronext Amsterdam, BAI

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, US from 8-11 January 2024.

Key Points: 
  • BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, US from 8-11 January 2024.
  • Dr. François Nader, Chair and Acting CEO, is scheduled to present a Company overview and participate in a Q&A session at 08:15 PST (16:15 GMT) on Thursday, 11 January 2024.
  • A live audio of the presentation will be available on the Investors section of the Company’s website, www.benevolent.com/investors/reports-and-presentations/ and a replay will be available shortly after the event.
  • Members of BenevolentAI’s Executive Leadership Team will be attending and available throughout the conference for meetings, see contact details below.

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Optical, Health, Clinical Trials, Atopic dermatitis, Principal, Body surface area, Therapy, Clinical trial, IGA, BAI, Patient, Safety, RASP, Pharmaceutical industry

Relative to baseline, over three months of treatment, improvement was observed in all patients.

Key Points: 
  • Relative to baseline, over three months of treatment, improvement was observed in all patients.
  • EASI thresholds for 50% improvement (EASI‑50), 75% improvement (EASI-75), and 90% improvement (EASI-90) were met in four patients (50%), three patients (38%), and one patient (13%), respectively.
  • Statistical significance was achieved for improvement in depression (HAM-D, p=0.02) and numerical improvement was observed for improvement in anxiety (BAI, p=0.1).
  • ET today, December 19, 2023, to discuss the top-line results of the Phase 2 clinical trial of ADX-629 in atopic dermatitis.

Wells Fargo Names Darlene Goins Head of Philanthropy and Community Impact, President of Wells Fargo Foundation

Retrieved on: 
Friday, December 8, 2023
Finance, Banking, Foundation, Professional Services, Philanthropy, NYSE, Multimedia, Management science, Wells Fargo, Small business, Public affairs, Prosperity Now, Stanford University, WFC, Housing, FICO, Growth, BAI (organization), BAI, Community Impact Newspaper

Wells Fargo & Company (NYSE:WFC) today announced that Darlene Goins is named head of Philanthropy and Community Impact and president of the Wells Fargo Foundation.

Key Points: 
  • Wells Fargo & Company (NYSE:WFC) today announced that Darlene Goins is named head of Philanthropy and Community Impact and president of the Wells Fargo Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20231208646694/en/
    Wells Fargo names Darlene Goins new head of Philanthropy and Community Impact and president of the Wells Fargo Foundation.
  • (Photo: Wells Fargo)
    Previously, Goins served as head of Diverse Customer Segments within Wells Fargo’s Consumer, Small & Business Banking, leveraging customer feedback, analytics, and insights to meet the needs of diverse customers.
  • In an earlier role, Goins served as head of Financial Health Philanthropy for the Wells Fargo Foundation, responsible for helping underserved communities by reducing debt, driving savings and advancing wealth-building.